Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2013-08-13 18:01:31
Reporting Period:
Filing Date:
Accepted Time:
2013-08-13 18:01:31
Original Submission Date:
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
884629 Actavis Inc. ACT Pharmaceutical Preparations (2834) 953872914
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1476493 A Robert Stewart Morris Corporate Center Iii
Parsippany NJ 07054
Pres-Global Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0033 Disposition 2013-08-02 14,564 $136.02 73,891 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. Includes shares of restricted stock issued pursuant to the Fourth Amendment and Restatement of the 2001 Incentive Award Plan of Actavis, Inc., as amended.
  2. This amendment to Form 4 is filed solely to correct the transaction code in Box 3 to reflect a sale rather than a forteiture of shares on the transaction date.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.45 to $136.44, inclusive. The reporting person undertakes to provide to Actaivs, Inc., any security holder of Actavis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.